Hepatic CD141+IFNλ+ DC subset: One against all?

Slides:



Advertisements
Similar presentations
EASL Clinical Practice Guidelines: Vascular diseases of the liver Journal of Hepatology Volume 64, Issue 1, Pages (January 2016) DOI: /j.jhep
Advertisements

Depression, anemia and health-related quality of life in chronic hepatitis C Amy A. Dan, Lisa M. Martin, Cathy Crone, Janus P. Ong, Denise W. Farmer, Thomas.
Omega 3 – Omega 6: What is right for the liver? Ashraf Mohammad El-Badry, Rolf Graf, Pierre-Alain Clavien Journal of Hepatology Volume 47, Issue 5, Pages.
Volume 63, Issue 1, Pages (July 2015)
Volume 46, Issue 3, Pages (March 2007)
Host – hepatitis C viral interactions: The role of genetics
Inflammasomes in liver diseases
Volume 50, Issue 4, Pages (April 2009)
MELD: the holy grail of organ allocation?
Lifestyle interventions for the treatment of non-alcoholic fatty liver disease in adults: A systematic review  Christian Thoma, Christopher P. Day, Michael.
Tiny RNA with great effects: miR-155 in alcoholic liver disease
An integration of deep viral suppression with sequential immune modulation (cocktail therapy) to restore antiviral capacity: The future of chronic hepatitis.
Geoffrey W McCaughan, Amany Zekry  Journal of Hepatology 
Pathological roles of purinergic signaling in the liver
Halis Simsek, Ali Shorbagi, Yasemin Balaban, Gonca Tatar 
Volume 51, Issue 6, Pages (December 2009)
Reactive oxygen species in the normal and acutely injured liver
Geoffrey W McCaughan, Amany Zekry  Journal of Hepatology 
Matthew T. Kitson, Stuart K. Roberts  Journal of Hepatology 
Volume 52, Issue 3, Pages (March 2010)
Volume 57, Issue 1, Pages 6-8 (July 2012)
NS5A inhibitors in the treatment of hepatitis C
Immigration and viral hepatitis
Regulatory T-cell directed therapies in liver diseases
Volume 66, Issue 1, Pages 1-4 (January 2017)
Ype P. de Jong, Charles M. Rice, Alexander Ploss  Journal of Hepatology 
Living donor liver transplantation: is the hype over?
Nicolas Moniaux, Jamila Faivre  Journal of Hepatology 
David G. Bowen, Christopher M. Walker  Journal of Hepatology 
miR-155-SOCS1 as a Functional Axis: Satisfying the Burden of Proof
Mesenchymal stromal cell therapy for liver diseases
Volume 44, Pages S19-S24 (January 2006)
Natural history and predictors of severity of chronic hepatitis C virus (HCV) and human immunodeficiency virus (HIV) co-infection  Anaïs Vallet-Pichard,
Regulatory T-cell directed therapies in liver diseases
Hepatitis C core protein – The “core” of immune deception?
Volume 61, Issue 1, Pages S108-S119 (November 2014)
Marc van der Valk, Hans L. Zaaijer, Arnon P. Kater, Janke Schinkel 
Volume 53, Issue 4, Pages (October 2010)
Volume 70, Issue 1, Pages (January 2019)
Volume 61, Issue 1, Pages S69-S78 (November 2014)
Volume 45, Issue 4, Pages (October 2006)
Volume 62, Issue 3, Pages (March 2015)
Genomic risk of hepatitis C-related hepatocellular carcinoma
Darius Moradpour, Arash Grakoui, Michael P. Manns 
Autophagy in the liver Journal of Hepatology
Volume 59, Issue 3, Pages (September 2013)
EASL Clinical Practice Guidelines: Wilson’s disease
HCMV jogs the ‘memory’ of NK cells in HBV
Bin Gao, Hua Wang, Fouad Lafdil, Dechun Feng  Journal of Hepatology 
Cannabinoid signaling and liver therapeutics
Volume 50, Issue 4, Pages (April 2009)
Arjan Boltjes, Dowty Movita, André Boonstra, Andrea M. Woltman 
Antiviral therapy for chronic hepatitis B: Challenges in Hong Kong
Paul C. Adams, James C. Barton  Journal of Hepatology 
Immigration and viral hepatitis
The potential of induced pluripotent stem cell derived hepatocytes
Clinical Practice Guidelines of the European Association for the study of the Liver – Advancing methodology but preserving practicability  Markus Cornberg,
Immunological techniques in viral hepatitis
Volume 63, Issue 1, Pages (July 2015)
Volume 51, Issue 2, Pages (August 2009)
Liam O’Mahony, PhD, Mübeccel Akdis, MD, PhD, Cezmi A. Akdis, MD 
Statins: Old drugs as new therapy for liver diseases?
Ana Lleo, M. Eric Gershwin, Alberto Mantovani, Pietro Invernizzi 
Pathogenesis of cholestatic hepatitis C
Chimeric mouse model of hepatitis B virus infection
Hepatitis E virus: Infection beyond the liver?
Eric Robinet, Thomas F. Baumert  Journal of Hepatology 
Host – hepatitis C viral interactions: The role of genetics
MELD: the holy grail of organ allocation?
Platelets arrive at the scene of fibrosis……studies
Presentation transcript:

Hepatic CD141+IFNλ+ DC subset: One against all? Claudia Wegscheid, Khalil Karimi, Gisa Tiegs  Journal of Hepatology  Volume 60, Issue 1, Pages 9-11 (January 2014) DOI: 10.1016/j.jhep.2013.10.007 Copyright © 2013 European Association for the Study of the Liver Terms and Conditions

Fig. 1 Possible role of CD141+ DC subsets in the immune response. Upon viral infection CD141+CLEC9A+ DCs become activated and release IFNlambda (IFN-λ). Subsequently, conventional CD8+ T cells are recruited to the liver to clear the infection. On the other hand, ILT3+ILT4+CD141+ DCs become activated with several stimuli and might induce the regulation of the immune response, e.g., by induction of regulatory T cells (Tregs). This might promote the healing and regeneration process in the liver. Journal of Hepatology 2014 60, 9-11DOI: (10.1016/j.jhep.2013.10.007) Copyright © 2013 European Association for the Study of the Liver Terms and Conditions